Evaluation of the diagnostic value of YiDiXie™-SS and YiDiXie™-HS in breast cancer

Yutong Wu[1,2,3#], Huimei Zhou[1,2,4#], Xutai Li[1,2,4#], Chen Sun[1,2,4], Zhenjian Ge[1,2,3], Wenkang Chen[1,2,3], Yingqi Li[1,2,5], Shengjie Lin[1,2,3], Pengwu Zhang[1,2], Wuping Wang[1,2,5], Siwei Chen[1,2,5], Wei Li[6], Hui Hu[8*], Xiaoling Liu[8*], Yongqing Lai[1,2*]

1 Department of Urology, Peking University Shenzhen Hospital, Shenzhen, 518036; 2Institute of Urology, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, 518036; 3 Shantou University Medical College, Shantou, Guangdong 515041; 4 The Fifth Clinical Medical College of Anhui Medical University, Hefei 230032; 5 Shenzhen University Health Science Center, Shenzhen, China 518055; 6 Shenzhen KeRuiDa Health Technology Co. , Ltd. , Shenzhen, 518071; 7 Department of Specialized Medicine, Peking University Shenzhen Hospital, Shenzhen, 518036; 8 Department of Breast and Thyroid Surgery, Peking University Shenzhen Hospital, Shenzhen, 518036.

# Contributed equally to this work.

*Correspondence: Yongqing Lai, Peking University Shenzhen Hospital, 1120 Lianhua Road, Shenzhen 518036, E mail: yqlord@163. com; Xiaoling Liu, Peking University Shenzhen Hospital, 1120 Lianhua Road, Shenzhen 518036, E mail: liuxiaoling97@aliyun.com; Hui Hu, Peking University Shenzhen Hospital, 1120 Lianhua Road, Shenzhen 518036, E mail: sapphiretjmu@163.com; Yanni Han, Peking University Shenzhen Hospital, 1120 Lianhua Road, Shenzhen 518036, E mail: 2522649101@qq.com.

Background: Breast cancer is a serious threat to women's health and breast cancer screening is of great importance. Breast ultrasound or mammography is widely used for screening or diagnosis of breast tumors, However, false-positive results on breast ultrasound or mammography can lead to unnecessary puncture biopsies, patients have to bear unnecessary mental pain, expensive examination costs, physical injury and other adverse consequences. False-negative results on breast ultrasound or mammography can lead to delayed treatment, and patients will therefore have to bear the adverse consequences of poor prognosis, expensive treatment, poor quality of life, and short survival. There is an urgent need to find a convenient, cost-effective and noninvasive method to reduce the false-positive rate and the false-negative rate of breast ultrasound or mammography. The aim of this study was to evaluate the diagnostic value of YiDiXie™-SS and YiDiXie™-HS in breast cancer.

Patients and methods: 816 subjects (malignant group, n=778; benign tumor group, n=38) were finally included in this study. The remaining serum samples were collected and tested by YiDiXie™ all-cancer detection kit. The sensitivity and specificity of YiDiXie™-SS and YiDiXie™-HS were evaluated respectively.

Results: The sensitivity of YiDiXie™-SS was 97.8% (95% CI: 96.5% - 98.6%; 761/778), and its specificity was 63.2% (95% CI: 47.3% - 76.6%; 24/38). The sensitivity of YiDiXie™-HS was 84.4% (95% CI: 81.7% - 86.8%; 657/778), and its specificity was 86.8% (95% CI: 72.7% - 94.2%; 33/38). The sensitivity of YiDiXie™-SS in breast ultrasound-positive patients was 97.8% (95% CI: 96.5% - 98.7%; 727/743), while the specificity was 63.6% (95% CI: 46.6% - 77.8%; 21/33). This means that the application of YiDiXie™-SS reduces the rate of breast ultrasound false positives by 63.6% (95% CI: 46.6% - 77.8%; 21/33) with essentially no increase in malignant tumor underdiagnosis. The sensitivity of YiDiXie™-HS in breast ultrasound-negative patients was 84.8% (95% CI: 60.1% - 93.3%; 28/33), and the specificity was 80.0% (95% CI: 37.6% - 99.0%; 4/5). This means that the application of YiDiXie™-HS reduces the rate of breast ultrasound false negatives by 84.8% (95% CI: 60.1% - 93.3%; 28/33). The sensitivity of YiDiXie™-SS in mammography-positive patients was 97.6% (95% CI: 95.8% - 98.6%; 485/497) and the specificity was 58.3% (95% CI: 32.0% - 80.7%; 7/12). This means that the application of YiDiXie™-SS reduces the false-positive rate of mammograms by 58.3% (95% CI: 32.0% - 80.7%; 7/12) with essentially no increase in malignant tumor underdiagnosis. The sensitivity of YiDiXie™-HS in mammography-negative patients was 85.7% (95% CI: 76.7% - 91.6%; 72/84), specificity was 100% (95% CI: 56.6% - 100%; 5/5). This means that the application of YiDiXie™-HS reduces the false-negative mammogram rate by 85.7% (95% CI: 76.7% - 91.6%; 72/84).

Conclusion: YiDiXie™-SS significantly reduces the false-positive rate of breast ultrasound or mammography-positive patients without increasing the number of under-diagnosed malignant tumors. YiDiXie™-HS dramatically reduces the false-negative rate of breast ultrasound or mammography. YiDiXie™-SS and YiDiXie™-HS has vital diagnostic value in breast cancer, and are expected to solve the problems of "high false-positive rate of breast ultrasound or mammography" and "high false-negative rate of breast ultrasound or mammography".

Clinical trial number: ChiCTR2200066840.

Key words: Breast cancer, Breast ultrasound, Mammography, False-positive, False-negative, YiDiXie™-SS, YiDiXie™-HS

INTRODUCTION

Breast cancer is the most common malignant tumor in women. The latest data show that in 2022, there will be 2,308,897 new cases of breast cancer globally, ranking 2nd in the global rate of new malignant tumors; there will be 665,684 new deaths, ranking 4th in the global mortality rate of malignant tumors[1]; and the incidence rate of breast cancer in 2022 has increased by 2% compared with that in 2020[1,2], and the prevalence continues to increase year by year. Currently, breast cancer is treated with a combination of surgical treatment, endocrine therapy, and targeted therapy depending on the tumor type[3]. In an epidemiological survey in the United States that included 11 common malignant tumors and the economic burden of disease, breast cancer topped the list with $39 billion in annual treatment expenditures[4]. The 5-year survival rate for stage I breast cancer patients in the United States from 2009-2015 was upwards of ninety percent, compared to only 27 percent for stage IV[5]. Breast cancer screening has been shown to improve cure rates[6-8]. Therefore, breast cancer screening can significantly improve the prognosis of breast cancer and reduce the financial burden of breast cancer patients. Therefore, breast cancer is a serious threat to women's health and breast cancer screening is of great importance.

Breast ltrasound or mammography is widely used in the screening or diagnosis of breast tumors, but breast ultrasound or mammography can produce a large number of false-positive results. According to the ultrasound BI-RADS grading system developed by the American College of Radiology (ACR), a diagnostic result in BI-RADS categories 4-5 is positive and requires histopathologic examination for final diagnosis[9]. Category 4 lesions have a wide range of malignancy risk spanning (2%-95%) and immediate pathologic biopsy is recommended[9]. Whereas the majority of biopsies of these 4a lesions are negative, the false-positive rate can be as high as 90%-98%[9]. False-positive results of breast ultrasound or mammography imply misdiagnosis of benign disease as malignancy. As breast ultrasound or mammography is positive, puncture biopsy is usually taken to obtain tissue specimens for pathologic diagnosis, from which the next step in the treatment plan is developed[10]. As a result, patients with false-positive breast ultrasound or mammography will have to bear the negative consequences of unnecessary puncture biopsy in terms of mental anguish, expensive examination costs, and physical injury. Therefore, there is an urgent need to find a convenient, cost-effective and non-invasive diagnostic method to reduce the false positive rate of breast ultrasound or mammography.

On the one hand, breast ultrasound or mammography can produce a large number of false-positive results. According to the ultrasound BI-RADS grading system developed by the American College of Radiology (ACR), a diagnosis of a BI-RADS ≤ 3 category is considered negative[9]. When a breast ultrasound or mammogram is negative, patients are usually taken for observation and regular follow-up [10]. A false negative breast ultrasound or molybdenum result implies a missed diagnosis of breast cancer, which will likely lead to a delay in treatment, progression of the malignancy, and possibly even development of advanced stages. Patients will thus have to bear the adverse consequences of poor prognosis, high treatment costs, poor quality of life, and short survival. Therefore, there is an urgent need to find a convenient, cost-effective and non-invasive diagnostic method to reduce the false-negative rate of breast ultrasound or molybdenum target.

Based on the detection of miRNAs in serum, Shenzhen KeRuiDa Health Technology Co., Ltd. has developed "YiDiXie ™ all-cancer test" (hereinafter referred to as the YiDiXie ™ test)[11]. With only 200 milliliters of whole blood or 100 milliliters of serum, the test can detect multiple cancer types, enabling detection of cancer at home[11]. The YiDiXie ™ test consists of three independent tests: YiDiXie ™ -HS, YiDiXie™-SS and YiDiXie™-D[11].

The purpose of this study is to evaluate the diagnostic value of YiDiXie™-SS and YiDiXie™-HS in breast cancer.

PATIENTS AND METHODS

Study design

This work is part of the sub-study "Evaluating the diagnostic value of the YiDiXie™ test in multiple tumors" of the SZ-PILOT study (ChiCTR2200066840).

SZ-PILOT is a prospective, observational, single-center study (ChiCTR2200066840). At the time of admission or physical examination, subjects who signed a pan-informed permission form for the donation of their remaining samples were considered included, and 0.5 milliliter of their remaining serum samples was taken for this investigation.

The participants and investigators in this study were blinded. The laboratory professionals who administered the YiDiXie™ test and the technicians of KeRuiDa Co. who determined the test findings were unaware of the participants' clinical information. The clinical specialists evaluating the individuals' clinical information were ignorant of the results of the YiDiXie™ test.

The Ethics Committee of Shenzhen Hospital of Peking University approved the study, which was carried out in accordance with the International Conference on Harmonization (ICH) Code of Practice for the Quality Management of Pharmaceutical Clinical Trials and the Declaration of Helsinki.

Participants

According to the ultrasound BI-RADS grading system developed by the American College of Radiology (ACR), a diagnostic result in BI-RADS categories 4-5 is positive[9].

Patients with breast ultrasound findings of BI-RADS category 4 or 5 were included in this study. The two groups were enrolled independently, and subjects who satisfied the inclusion criteria were added one after the other.

This study initially included hospitalized patients with "suspected (solid or hematological) malignancy" who signed a pan-informed agreement to donate the remaining samples.

Subjects having a postoperative pathologic diagnostic of "breast cancer" were placed in the prostate cancer group, whereas those with a postoperative pathologic diagnosis of benign disease were put in the benign group. Participants who had unclear pathologic results were excluded from the research. Some of these malignant group were used in the previous study of our group[11].

The study eliminated subjects who did not pass the serum sample quality test prior to the YiDiXie™ test . For further information on enrollment and exclusion, please see the subject group's earlier article[11].

Sample collection, processing

The serum samples utilized in this investigation were obtained from serum leftover from a routine medical consultation, eliminating the need for extra blood sampling. Approximately 0.5 ml of serum was collected from the remaining serum of subjects in the Medical Laboratory and stored at -80℃ for subsequent use in the YiDiXie™ test.

The YiDiXie™ test

The YiDiXie™ test is done using the YiDiXie™ all-cancer detection kit. The YiDiXie™ test is an in vitro diagnostic kit developed and manufactured by Shenzhen KeRuiDa Health Technology Co. Ltd.. It determines whether a subject has cancer by looking for the expression levels of several dozen miRNA biomarkers in their serum. It maintains the specificity and increases the sensitivity of a wide range of malignancies by integrating these independent assays in a contemporaneous testing format and predefining suitable criteria for each miRNA biomarker to guarantee that each miRNA marker is highly specific.

The YiDiXie™ test consists of three tests with

very different characteristics: YiDiXie ™ -Highly Sensitive (YiDiXie™-HS) , YiDiXie™-Super Sensitive (YiDiXie™-SS) and YiDiXie™-Diagnosis(YiDiXie™ -D). The development of YiDiXie ™ -HS took specificity and sensitivity into consideration. The number of miRNA testing was greatly enhanced with YiDiXie ™ -SS in order to obtain very high sensitivity for all clinical stages of all malignant tumor types. YiDiXie™-D dramatically increases the diagnostic threshold of a single miRNA test to

achieve very high specificity (very low misdiagnosis rate) for all malignancy types.

Perform the YiDiXie™ test according to the instructions for the YiDiXie™ all-cancer detection kit. Refer to our prior article for detailed procedures[11].

The raw results were analyzed by the laboratory technicians of KeRuiDa Co., and the results of the YiDiXie™ test were determined to be "positive" or "negative".

Diagnosis of breast ultrasound and mammography

The diagnosis of breast ultrasound and mammography was determined based on the BI-RADS grade of the included cases that had a BI-RADS grade. A BI-RADS grade of 4 or 5 is considered "positive" and a BI-RADS grade of ⩽3 is considered "negative"[9].If the included cases did not have a BI-RADS grade, the results were judged as "positive" or "negative" according to their

diagnostic conclusion.

If the diagnostic conclusion was positive, more positive, or tended to be malignant, the result was judged as "positive". If the diagnosis is positive, more positive or inclined to benign disease, or if the diagnosis is ambiguous, the test result is judged as "negative".

Clinical data collection

For this study, clinical, pathological, laboratory, and imaging data were retrieved from the subjects' hospitalized medical records or physical

examination reports. The clinical staging was evaluated by trained clinicians according to the AJCC staging manual (7th or 8th edition)[12,13].

Statistical analyses

Descriptive statistics were reported for demographic and baseline characteristics. Number and percentage of subjects in each category were calculated for categorical variables, and minimum and maximum values were calculated for total number of subjects (n), mean, standard deviation

(SD) or standard error (SE), median, first quartile (Q1), third quartile (Q3), and minimum and maximum values for continuous variables. Wilson (score) method was used to calculate 95% confidence intervals (CI) for multiple indicators.

RESULTS

Participant disposition

816 study participants were involved in this research (n = 778 cases for the malignant group and 38 cases for the benign group). The 816 participants' clinical and demographic details are listed in Table 1.

In terms of clinical and demographic traits, the two study subject groups were similar (Table 1). The mean (standard deviation) age was 49.2 (12.06) years.

Table 1. Participants' demographic and clinical manifestation

	Malignant (n = 778)		Benign (n = 38)		Total (N = 816)	
Age, years						
Mean (SD)	49.5	(12.00)	43.3	(11.78)	49.2	(12.06)
Median (Q1,Q3)	48	(41, 57)	42	(35, 51)	48	(41, 57)
Min, max	22,	88	20,	71	20,	88
Age, group, n (%)						
<50	426	(54.8)	28	(73.7)	454	(55.6)
≥50	352	(45.2)	10	(26.3)	362	(44.4)
<65	684	(87.9)	36	(94.7)	720	(88.2)
≥65	94	(12.1)	2	(5.3)	96	(11.8)
Body mass index (kg/m2)						
n	763		37		800	
Mean (SD)	23.1	(3.02)	22.9	(3.87)	23.1	(3.06)
Median (Q1,Q3)	22.8	(21.1, 24.8)	22.3	(20.7, 26.0)	22.8	(21.0, 24.8)
Min, max	14.6	35.9	16.3	32.0	14.6	35.9
Body mass index category, n (%)						
Underweight	31	(4.0)	5	(13.2)	36	(4.4)
Benign	475	(61.1)	21	(55.3)	496	(60.8)
Overweight	206	(26.5)	7	(18.4)	213	(26.1)
Obese	51	(6.6)	4	(10.5)	55	(6.7)
Missing	15	(1.9)	1	(2.6)	16	(2.0)
AJCC clinical stage						
Stage 0	74	(9.5)			74	(9.5)
Stage I	288	(37.0)			288	(37.0)
Stage II	329	(42.3)			329	(42.3)
Stage III	87	(11.2)			87	(11.2)

Q1,Q3, first quartile, third quartile; SD, standard deviation.

Diagnostic Performance of YiDiXie™-SS

As shown in Table 2, the sensitivity of YiDiXie™-SS was 97.8% (95% CI: 96.5% - 98.6%; 761/778), and its specificity was 63.2% (95% CI: 47.3% - 76.6%; 24/38).

Table 2. The performance of YiDiXie™-SS			
	Malignant	Benign	Total
	778	38	816
Positive	761	14	775
Negative	17	24	41
SEN = 761/778 = 97.8% (96.5% - 98.6%)		SPE = 24/38 = 63.2% (47.3% - 76.6%)	

SEN, Sensitivity. SPE, Specificity. Two-sided 95% Wilson confidence intervals were calculated.

Diagnostic performance of YiDiXie™-HS

As shown in Table 3, the sensitivity of YiDiXie™-HS was 84.4% (95% CI: 81.7% - 86.8%; 657/778), and its specificity was 86.8% (95% CI: 72.7% - 94.2%; 33/38).

Table 3. The performance of YiDiXie™-HS			
	Malignant	Benign	Total
	778	38	816
Positive	657	5	662
Negative	121	33	154
SEN = 657/778 = 84.4% (81.7% - 86.8%)		SPE = 33/38 = 86.8% (72.7% - 94.2%)	

SEN, Sensitivity. SPE, Specificity. Two-sided 95% Wilson confidence intervals were calculated.

Distribution of breast ultrasound results

Breast ultrasound results were positive in 776/814 subjects in both groups, including 743/776 in the malignant group and 33/38 in the benign group, and negative in 38/814 subjects in both groups, including 33/776 in the malignant group and 5/38 in the benign group.

Diagnostic performance of YiDiXie™-SS in breast ultrasound-positive patients

In order to solve the problem of high false-positive rate of breast ultrasound, YiDiXie™-SS was applied to breast ultrasound-positive patients. As shown in Table 4, the sensitivity of YiDiXie™-SS in breast ultrasound-positive patients was 97.8% (95% CI: 96.5% - 98.7%; 727/743), while the specificity was 63.6% (95% CI: 46.6% - 77.8%; 21/33). This means that the application of YiDiXie™-SS reduces the rate of breast ultrasound false positives by 63.6% (95% CI: 46.6% - 77.8%; 21/33) with essentially no increase in malignant tumor underdiagnosis.

Table 4. The performance of YiDiXie™-SS test in breast ultrasound-positive patients		
	Malignant	Benign	Total
	743	33	776
Positive	727	12	739
Negative	16	21	37
SEN = 727/743 = 97.8% (96.5% - 98.7%)	SPE = 21/33 = 63.6% (46.6% - 77.8%)	

SEN, Sensitivity. SPE, Specificity. Two-sided 95% Wilson confidence intervals were calculated.

Diagnostic performance of YiDiXie™-HS in breast ultrasound-negative patients

In order to solve the problem of high false-negative rate of breast ultrasound, YiDiXie™-HS was applied to breast ultrasound-negative patients. As shown in Table 5, the sensitivity of YiDiXie™-HS in breast ultrasound-negative patients was 84.8% (95% CI: 60.1% - 93.3%; 28/33), and the specificity was 80.0% (95% CI: 37.6% - 99.0%; 4/5). This means that the application of YiDiXie™-HS reduces the rate of breast ultrasound false negatives by 84.8% (95% CI: 60.1% - 93.3%; 28/33).

Table 5. The performance of YiDiXie™-HS test in breast ultrasound-negative patients		
	Malignant	Benign	Total
	33	5	38
Positive	28	1	29
Negative	5	4	9
SEN = 28/33 = 84.8% (60.1% - 93.3%)	SPE = 4/5 = 80.0% (37.6% - 99.0%)	

SEN, Sensitivity. SPE, Specificity. Two-sided 95% Wilson confidence intervals were calculated.

Distribution of mammography results

Mammography results were positive in 509/598 subjects in both groups, including 497/581 in the malignant group and 12/17 in the benign group, and negative in 89/598 subjects in both groups, including 84/581 in the malignant group and 5/17 in the benign group.

Diagnostic performance of YiDiXie™-SS in mammography-positive patients

In order to solve the problem of high false-positive rate of mammography, YiDiXie™-SS was applied to mammography-positive patients.As shown in Table 6, the sensitivity of YiDiXie™-SS was 97.6% (95% CI: 95.8% - 98.6%; 485/497) and the specificity was 58.3% (95% CI: 32.0% - 80.7%; 7/12). This means that the application of YiDiXie™-SS reduces the false-positive rate of mammograms by 58.3% (95% CI: 32.0% - 80.7%; 7/12) with essentially no increase in malignant tumor underdiagnosis.

Table 6. The performance of YiDiXie™-SS test in mammography-positive patients			
	Malignant	Benign	Total
	497	12	509
Positive	485	5	490
Negative	12	7	19
SEN = 485/497 = 97.6% (95.8% - 98.6%)		SPE = 7/12 = 58.3% (32.0% - 80.7%)	

SEN, Sensitivity. SPE, Specificity. Two-sided 95% Wilson confidence intervals were calculated.

Diagnostic performance of YiDiXie™-HS in mammography-negative patients

In order to solve the challenge of high false-negative rate of mammography, YiDiXie™-HS was applied to mammography-negative patients.As shown in Table 7, the sensitivity of YiDiXie™-HS in mammography-negative patients was 85.7% (95% CI: 76.7% - 91.6%; 72/84), specificity was 100% (95% CI: 56.6% - 100%; 5/5). This means that the application of YiDiXie™-HS reduces the false-negative mammogram rate by 85.7% (95% CI: 76.7% - 91.6%; 72/84).

Table 7. The performance of YiDiXie™-HS test in mammography-negative patients			
	Malignant	Benign	Total
	84	5	89
Positive	72	0	72
Negative	12	5	17
SEN = 72/84 = 85.7% (76.7% - 91.6%)		SPE = 5/5 = 100% (56.6% - 100%)	

SEN, Sensitivity. SPE, Specificity. Two-sided 95% Wilson confidence intervals were calculated.

DISCUSSION

Clinical significance of YiDiXie™-SS in breast ultrasound or mammography-positive patients

There are 3 very different tests in the 1-Drop™ Test: YiDiXie™-HS, YiDiXie™-SS, and YiDiXie™-D. YiDiXie™-HS has both high sensitivity and high specificity. YiDiXie™-SS has very high sensitivity for all types of malignant tumors, but slightly lower specificity. YiDiXie™-D has very high specificity for all types of malignant tumors, but relatively low sensitivity.

For breast ultrasound or mammography-positive patients, both sensitivity and specificity of further diagnostic methods are important. On one hand, the sensitivity is critical. A lower sensitivity means a higher rate of false negatives. When the results of this diagnostic method are negative, the diagnosis usually ends for that patient. A higher false-negative rate means that more malignant tumors are missed, which will lead to a delay in their treatment, progression of the malignant tumor, and possibly even development of advanced stages. The patients will thus be obliged to bear the adverse consequences of poor prognosis, poor quality of life, and high cost of treatment.

On the other hand, the specificity is very important. Lower specificity means a higher rate of false positives. When the diagnosis is positive, breast tumors are usually biopsied by puncture biopsy. A higher false positive rate means that more cases of benign tumors undergo puncture biopsy. It definitely leads to a significant increase in emotional distress, costly procedures or tests, physical injuries, and other negative consequences for the patient.

Consequently, there is a trade-off between "fewer malignant tumors missed" and "fewer benign tumors misdiagnosed" when it comes to sensitivity and specificity. When non-breast cancer cases is mistakenly identified as malignant tumor, aspiration biopsy is typically performed instead of surgical resection. Therefore, false-positive breast ultrasound does not lead to serious consequences of organ loss. Therefore, for breast ultrasound-positive patients, "fewer missed diagnoses of malignant tumors" is considerably more essential than "fewer misdiagnoses of benign tumors." Therefore, YiDiXie™-SS was chosen for reducing the false-positive rates of breast ultrasound rather than YiDiXie™-HS or YiDiXie™-D.

As shown in Tables 4 and 6, YiDiXie™-SS had a sensitivity of 97.8% (95% CI: 96.5% - 98.7%; 727/743), 97.6% (95% CI: 95.8% - 98.6%; 485/497), and specificity of 63.6% (95% CI: 46.6% - 77.8%; 21/33), 58.3% (95% CI: 32.6% - 77.8%; 21/33) in breast ultrasound or mammography-positive patients. These results indicate that YiDiXie™-SS reduces false positives on breast ultrasound or mammography by 63.6% (95% CI: 46.6% - 77.8%; 21/33), 58.3% (95% CI: 32.0% - 80.7%; 7/12), respectively, while maintaining sensitivity close to 100%.

As mentioned above, missed diagnosis of breast cancer means delayed treatment, while false positive results of breast ultrasound or mammography mean puncture biopsy. The above results imply that YiDiXie™-SS dramatically reduces the probability of false puncture biopsies of benign breast tumors with essentially no increase in malignant tumor underdiagnosis.

In other words, YiDiXie™-SS drastically decreases the mental suffering, expensive examination or surgery costs, physical injuries, and other adverse consequences for breast ultrasound or mammography-positive patients without basically increasing the delayed treatment of malignant tumors. Therefore, YiDiXie™-SS well fulfills the clinical demand and has important clinical significance and broad prospective application.

Clinical significance of YiDiXie™-HS in breast ultrasound or mammography-negative patients

For breast ultrasound or mammography-negative patients, both the sensitivity and specificity of further diagnostic methods are of great importance. On the one hand, sensitivity is

crucial. Higher false-negative rates mean that more malignancies are missed. On the other hand, specificity is crucial. Higher false-positive rates mean more benign tumors are misdiagnosed. In general, benign breast tumors misdiagnosed as malignant tumors usually undergo puncture biopsy rather than radical resection. Therefore, false-positive breast ultrasound does not lead to serious consequences of organ removal. Thus, for breast ultrasound or mammography-negative patients, "fewer malignant tumors missed" is more important than "fewer benign tumors misdiagnosed".

In addition, the negative predictive value is higher in breast ultrasound or mammography-negative patients. In this way, both higher false-positive and false-negative rates can lead to significant harm. Therefore, YiDiXie™-HS, with its high sensitivity and specificity, was chosen

to reduce the breast ultrasound or mammography false-negative rate.

As shown in Tables 5 and 7, the sensitivity of YiDiXie ™ -HS in breast ultrasound or mammography-negative patients was 84.8% (95% CI: 60.1% - 93.3%; 28/33), 85.7% (95% CI: 76.7% - 91.6%; 72/ 84), and specificity was 80.0% (95% CI: 37.6% - 99.0%; 4/5), 100% (95% CI: 56.6% - 100%; 5/5). This means that YiDiXie ™ -HS reduced false negatives on breast ultrasound or mammogram by 84.8% (95% CI: 60.1% - 93.3%; 28/33), 85.7% (95% CI: 76.7% - 91.6%; 72/84), respectively

The above results imply that YiDiXie ™ -HS significantly reduces the probability of missing malignant tumors with false-negative results on breast ultrasound or mammography. Therefore, YiDiXie™-HS meets the clinical needs well and has important clinical significance and wide application prospects.

YiDiXie™-SS and YiDiXie™-HS is expected to solve two problems of breast tumor

First, YiDiXie™-SS significantly reduces the risk of misdiagnosis of benign breast tumors as breast cancer. On the one hand, YiDiXie™-SS substantially reduces the probability of incorrect puncture biopsy of benign breast tumors with essentially no increase in breast cancer missed diagnosis. As shown in Tables 4 and 6, YiDiXie™-SS reduced the magnitude of false-positive breast ultrasound or molybdenum target by 63.6% (95% CI: 46.6% - 77.8%; 21/33), and 58.3% (95% CI: 32.0% - 80.7%; 7/12), respectively, with essentially no increase in breast cancer missed diagnosis. Thus, YiDiXie ™ -SS significantly reduces the range of adverse outcomes associated with unnecessary mammocentesis biopsies with essentially no increase in delayed treatment of breast cancer.

On the other hand, YiDiXie ™ -SS greatly eliminates nonessential workload for clinicians and contributes to the timely treatment of malignant tumor cases that would otherwise be delayed. When breast ultrasound or mammography is positive, patients usually undergo puncture biopsies. The availability of these biopsies is directly dependent on the number of clinicians. In many

parts of the world, puncture biopsies are not performed until appointments have been made for months or even more than a year. It inevitably slows down the treatment of malignancy cases, and therefore it is not uncommon for breast tumor patients awaiting treatment to develop malignancy progression or even distant metastases.

As shown in Tables 4 and 6, YiDiXie ™ -SS reduced the magnitude of false-positive breast ultrasound or molybdenum target by 63.6% (95% CI: 46.6% - 77.8%; 21/33), and 58.3% (95% CI: 32.0% - 80.7%; 7/12), respectively, with essentially no increase in breast cancer missed diagnosis. As a result, YiDiXie ™ -SS significantly relieves physician of unnecessary workload and facilitates the timely treatment of malignant tumors that would otherwise be delayed.

Second, YiDiXie™-HS significantly reduces the risk of breast cancer being missed. When a breast ultrasound or mammogram is negative, the possibility of breast cancer is usually ruled out for the time being. The high false-negative rate of breast ultrasound or mammography results in a large number of breast cancer patients delaying

treatment. As shown in Tables 5 and 7, YiDiXie™ -HS reduced false-negative breast ultrasound or mammography by 84.8% (95% CI: 60.1% - 93.3%; 28/33), 85.7% (95% CI: 76.7% - 91.6%; 72/84), respectively. As a result, YiDiXie™-HS significantly reduces the likelihood of missed diagnosis of malignant tumors due to false-negative results on breast ultrasound or mammography, and facilitates timely diagnosis and treatment of breast cancer patients who would otherwise be delayed in treatment.

Final, the YiDiXie™ test enables "just-in-time diagnosis" for breast tumor patients. On one hand, the YiDiXie™ test only requires microscopic amounts of blood, allowing patients to complete the diagnostic process non-invasively without leaving their homes. A single YiDiXie™ test needs only 20 microliters of serum, which is approximately the same amount as one drop of whole blood (one drop of whole blood is about 50 microliters, which yields 20-25 microliters of serum). Given the pre-test sample quality assessment and 2-3 repetitions, 0.2 mL of whole blood is enough to complete the YiDiXie™ test. The 0.2 mL of finger blood can be collected at home by the average patient using a finger blood collection needle, instead of requiring venous blood collection by medical personnel, allowing the patient to complete the diagnostic process non-invasively without having to leave their home.

On the other hand, the diagnostic capacity of the YiDiXie™ test is almost limitless. Figure 1 shows the basic flow chart of the YiDiXie™ test, which shows that the YiDiXie™ test does not require both a doctor and medical equipment, and does not require medical personnel to collect blood.

Thus, the YiDiXie™ test is absolutely independent of the number of clinicians and healthcare organizations, and has a nearly unlimited testing capacity. Therefore, the YiDiXie™ test enables "just-in-time" diagnosis of breast ultrasound-positive patients without the need for patients to wait anxiously for an appointment.

In short, YiDiXie™-SS and YiDiXie™-HS have important diagnostic value in breast cancer, and are expected to solve the two difficult problems of "too high false-positive rate of breast ultrasound or mammography" and "too high false-negative rate of breast ultrasound or mammography" in breast tumors.

Limitations of the study

Firstly, this study had a small number of cases and a clinical study with a larger sample size is needed for further evaluation in the future.

Secondly, this was an inpatient malignant tumor case-benign tumor control study, and future cohort studies of breast tumor patients are needed for further evaluation.

Finally, the current study was a single-center study, which may have led to some degree of bias in the results of this study. A multicenter study is needed for further evaluation in the future.

Figure 1. Basic flowchart of the YiDiXie™ test.

CONCLUSION

YiDiXie ™ -SS significantly reduces the false-positive rate of breast ultrasound or mammography-positive patients without increasing the number of under-diagnosed malignant tumors. YiDiXie ™ -HS dramatically reduces the false-negative rate of breast ultrasound or mammography. YiDiXie ™ -SS and YiDiXie ™ -HS has vital diagnostic value in breast cancer, and are expected to solve the problems of "high false-positive rate of breast ultrasound or mammography" and "high false-negative rate of breast ultrasound or mammography".

FUNDING

This study was supported by Shenzhen High-level Hospital Construction Fund, Clinical Research Project of Peking University Shenzhen Hospital (LCYJ2020002, LCYJ2020015, LCYJ2020020, LCYJ2017001).

REFERENCES

1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2024.

2. Sung H, Ferlay J, Siegel R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209-49.

3. Waks A G, Winer E P. Breast Cancer Treatment: A Review [J]. JAMA, 2019, 321(3): 288-300.

4. Iadeluca L, Mardekian J, Chander P, et al. The burden of selected cancers in the US: health behaviors and health care resource utilization [J]. Cancer Management and Research, 2017, Volume 9: 721-30.

5. Desantis C E, Ma J, Gaudet M M, et al. Breast cancer statistics, 2019 [J]. CA: a cancer journal for clinicians, 2019, 69(6): 438-51.

6. Lauby-Secretan B, Loomis D, Straif K. Breast-Cancer Screening — Viewpoint of the IARC Working Group [J]. New England Journal of Medicine, 2015, 373(15): 1478-9.

7. Marmot M G, Altman D G, Cameron D A, et al. The benefits and harms of breast cancer screening: an independent review [J]. British Journal of Cancer, 2013, 108(11): 2205-40.

8. Olsen A H, Lynge E, Njor S H, et al. Breast cancer mortality in Norway after the introduction of mammography screening [J]. International Journal of Cancer, 2012, 132(1): 208-14.

9. Baert A L. Breast Imaging Reporting and Data System (BI-RADS) [J]. 2013.

10. Gradishar W J, Anderson B O, Balassanian R, et al. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2015 [J]. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13(4): 448-75.

11. Chen Sun, Chong Lu, Yongjian Zhang, et al. Evaluation of the Multi-Cancer Early Detection (MCED) value of YiDiXie™-HS and YiDiXie™-SS [J]. medRxiv, 2024: doi: 10.1101/2024.03.11.24303683.

12. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and Winchester DP: The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 67: 93-99, 2017.

13. Edge SB and Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17: 1471-4, 2010.